Collegium Pharmaceutical Company Profile (NASDAQ:COLL)

Analyst Ratings

Consensus Ratings for Collegium Pharmaceutical (NASDAQ:COLL) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.25 (145.39% upside)

Analysts' Ratings History for Collegium Pharmaceutical (NASDAQ:COLL)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Piper Jaffray Cos.Reiterated RatingBuy$26.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Needham & Company LLCReiterated RatingBuy$28.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Janney Montgomery ScottInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016William BlairInitiated CoverageOutperform$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Jefferies GroupInitiated CoverageBuy$20.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/10/2016Q1($0.60)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.45)($0.46)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.30)($0.46)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.29)($0.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.60)($0.42)($0.51)
Q2 20162($0.74)($0.45)($0.60)
Q3 20162($0.85)($0.63)($0.74)
Q4 20162($0.86)($0.60)($0.73)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Collegium Pharmaceutical (NASDAQ:COLL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/12/2015John Gordon FreundDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015Longitude Capital Partners, LlMajor ShareholderBuy200,000$12.00$2,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)
DateHeadline
07/20/16 10:31 AMCollegium Pharmaceutical Incorporated (NASDAQ:COLL) Short Interest Increased By 25.16% - Consumer Eagle
07/20/16 10:31 AMStock Moving Lower for the Month; Investor Update on Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Engelwood Daily
07/20/16 10:31 AMEarnings Focus and Crowd Sourced Sentiment Review for Collegium Pharmaceutical Inc (NASDAQ:COLL) - TGP
07/19/16 03:24 PMCould Collegium Pharmaceutical Inc See a Reversal After Having Formed Several Months Descending Triangle Chart ... - Consumer Eagle
07/19/16 03:24 PMShares Losing Ground in Session: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - TGP
07/16/16 03:15 PMCollegium Pharmaceutical Inc (NASDAQ:COLL) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/16/16 05:49 AMAnalyst Target and Average Rating Watch: Collegium Pharmaceutical Inc (NASDAQ:COLL) - Press Telegraph
07/14/16 03:34 PMCollegium Pharmaceutical Incorporated (NASDAQ:COLL) Shorted Shares Increased By 11.59% - Consumer Eagle
07/14/16 03:34 PMCollegium Pharmaceutical Inc Stock Momentum at Critical Inflection Point - CML News
07/13/16 11:21 AMCollegium Pharmaceutical Inc (NASDAQ:COLL) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 11:21 AMShares Losing Ground for the Month; Investor Alert on Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Engelwood Daily
07/12/16 07:34 AMStock Volatility Focus for: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Engelwood Daily
07/10/16 03:12 PMNext Weeks Broker Price Targets For Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Fiscal Standard
07/10/16 03:12 PMNext Weeks Broker Price Targets For Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Fiscal Standard
07/08/16 10:39 AMCan Collegium Pharmaceutical Inc (NASDAQ:COLL) Improve on the Earnings Front? - Engelwood Daily
07/08/16 10:39 AMCompany Stock Focus for Collegium Pharmaceutical Inc (NASDAQ:COLL): Which Way Will Shares Head? - Press Telegraph
07/07/16 08:36 PMCollegium Pharmaceutical Inc Forms Bullish Descending Triangle Pattern; Strong Momentum for Buyers Coming - Press Telegraph
07/07/16 10:16 AMStock Tracking Down This Month; Investor Alert on Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Engelwood Daily
07/07/16 10:16 AMCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Current Analyst Ratings - Fiscal Standard
07/06/16 03:15 PMCollegium to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [GlobeNewswire] - CANTON, Mass., July 06, 2016-- Collegium Pharmaceutical, Inc. today announced that management will present at Cantor Fitzgerald’ s 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 8 a.m. The ...
07/05/16 08:05 AMCollegium Pharmaceutical Incorporated (NASDAQ:COLL) Short Interest Increased By 11.59% - Engelwood Daily
07/01/16 03:22 PMTracking Stock Volatility for: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Engelwood Daily
06/30/16 10:46 AMGlobal Pain Therapeutics Market Trends & R&D Insights, 2020
06/29/16 03:17 PMCollegium Pharmaceutical Inc (NASDAQ:COLL) Company Rating and Target Watch - Telanagana Press
06/29/16 10:40 AMEY Announces Winners for the EY Entrepreneur Of The Year® 2016 New England Award
06/28/16 08:12 AMIs Selling Collegium Pharmaceutical Inc Here a Winning Strategy? - Engelwood Daily
06/27/16 04:01 PMCollegium CEO Michael Heffernan Named EY Entrepreneur of the Year - [at noodls] - CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium's CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category ...
06/27/16 07:53 AMShare Update and Earnings Review for Collegium Pharmaceutical Inc (NASDAQ:COLL) - Press Telegraph
06/25/16 07:12 AMCovering the Bases on Collegium Pharmaceutical Inc (NASDAQ:COLL): Where is the Stock Going? - Press Telegraph
06/25/16 07:12 AMCollegium Pharmaceutical Inc (NASDAQ:COLL) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 04:48 PMCollegium Pharmaceutical : Announces Positive Topline Results for Hydrocodone DETERx Clinical Study
06/22/16 03:28 PMCollegium introduces Xtampza ER capsules in US
06/22/16 07:19 AMCollegium Announces Positive Topline Results for Hydrocodone DETERx® Clinical Study - [at noodls] - CANTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a clinical study evaluating Hydrocodone DETERx as a second product ...
06/21/16 08:05 AMKeryx Biopharmaceuticals Appoints Two New Board Members
06/20/16 03:19 PMAllergy Treatment Market 2016-2026 Shares, Trend and Growth Report
06/20/16 09:40 AMCollegium Pharma (COLL) Says Xtampza ER Now Commercially Available - StreetInsider.com
06/20/16 09:40 AMCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 08:19 AMCollegium Announces Commercial Launch of Xtampza® ER - [at noodls] - CANTON, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the commercial launch of XtampzaER (oxycodone) extended-release (ER) capsules in the United ...
06/14/16 07:39 AMCOLLEGIUM PHARMACEUTICAL, INC : Submission of Matters to a Vote of Security Holders (form 8-K)
06/13/16 04:02 PMCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 09:27 PMCollegium Pharmaceutical Inc (NASDAQ:COLL) Stock Update & Estimates - Stock Tick Tock
06/03/16 11:53 AMShare Rating Focus on Collegium Pharmaceutical Inc (NASDAQ:COLL) - HNN
06/02/16 03:05 PMCollegium Announces Poster Presentations for Xtampza™ ER at the International Conference on Opioids - [GlobeNewswire] - CANTON, Mass., June 02, 2016-- Collegium Pharmaceutical, Inc. today announced that it will present data on the use of Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent ...
06/02/16 12:00 PMCollegium Pharmaceutical, Inc. :COLL-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/02/16 11:11 AMCollegium Pharmaceutical Incorporated (NASDAQ:COLL) Short Interest Increased By 4.9% - HNN - Collegium Pharmaceutical Incorporated (NASDAQ:COLL) Short Interest Increased By 4.9%HNNCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The company has a market cap of $388.40 million. The Firm focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the ...
06/02/16 11:11 AMTarget Price and Stock Performance Rundown for Collegium Pharmaceutical Inc (NASDAQ:COLL) - HNN - Target Price and Stock Performance Rundown for Collegium Pharmaceutical Inc (NASDAQ:COLL)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Collegium Pharmaceutical Inc ...and more »
06/02/16 09:45 AMCollegium to Present at Jefferies and William Blair Conferences - [at noodls] - CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: Jefferies Healthcare ...
06/01/16 09:30 PMBroker Watchlist: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Share Trading News - Broker Watchlist: Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Share Trading News05/25/2016 – Collegium Pharmaceutical, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 26 price target on the stock. 03/15/2016 – Janney Montgomery Scott began new coverage on Collegium Pharmaceutical, ...Collegium Pharmaceutical Inc (COLL) Rating Lowered to Sell at Zacks Investment ResearchLet Me Know About ThisCurrent Price Targets For Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Risers & Fallersall 4 news articles »
05/31/16 09:04 PMThe Growth Forecast For Collegium Pharmaceutical Inc (NASDAQ:COLL) - RealistInvestor.com - The Growth Forecast For Collegium Pharmaceutical Inc (NASDAQ:COLL)RealistInvestor.comWall Street renowned brokerages following Collegium Pharmaceutical Inc (NASDAQ:COLL) have now given a mean price target of $29.25 on its stock. After accomplishing a methodical study, the analysts have specified a target price range. The intense high ...
05/31/16 12:14 AMAfter Last Week What Do Analysts Think Of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Share Trading News - After Last Week What Do Analysts Think Of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Share Trading News05/25/2016 – Collegium Pharmaceutical, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 26 price target on the stock. 03/15/2016 – Janney Montgomery Scott began new coverage on Collegium Pharmaceutical, ...

Social

About Collegium Pharmaceutical

Collegium Pharmaceutical logoCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication. Xtampza has the same active ingredient as OxyContin OP, which is the abuse-deterrent, extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not change its drug release profile.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: COLL
  • CUSIP:
Key Metrics:
  • Previous Close: $11.92
  • 50 Day Moving Average: $13.516
  • 200 Day Moving Average: $16.573
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $282.91M
  • Beta: 0.13
  • Current Year EPS Consensus Estimate: $-3.08 EPS
  • Next Year EPS Consensus Estimate: $-2.01 EPS
Additional Links:
Collegium Pharmaceutical (NASDAQ:COLL) Chart for Tuesday, July, 26, 2016